Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAB-176 Safety and PK in Healthy Adults
NCT04471038Phase 1Completed
- Sponsor
- SAB BIO
- Start
- Jul 2020
- Primary completion
- Apr 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SAB-176 in influenza (5 arms), sponsored by SAB BIO. Primary endpoint: Number of Participants Having Adverse Events at 90 days. Started Jul 2020; status: completed.
02
Drugs
SAB-176
03
Conditions
influenza
Beyond the preview
Go deeper on NCT04471038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04471038.